SGLT2 inhibitors reduced the composite of cardiovascular death or first heart failure hospitalization by 23% (pooled HR 0.77, 95% CI 0.72–0.82, p < 0.0001; I2 = 28%, τ2 = 0.003, prediction interval 0.68–0.87) using a Hartung–Knapp-adjusted random-effects model (Figure 2A). Here, SLC5A2 is linked to heart failure.